• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report.

作者信息

Criscuolo M, Salmanton-García J, Fracchiolla N, Dragonetti G, Khanna N, Weinbergerová B, Schönlein M, Machado M, Labrador J, Kolditz M, Itri F, Gomes Da Silva M, Bonuomo V, Sciumè M, Nunes Rodrigues R, Gräfe S, Marchesi F, Cornely O A, Pagano L

机构信息

Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy.

University of Cologne, Faculty of Medicine, and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.

出版信息

J Investig Allergol Clin Immunol. 2023 Jun 15;33(3):225-227. doi: 10.18176/jiaci.0845. Epub 2022 Jul 27.

DOI:
10.18176/jiaci.0845
PMID:35894666
Abstract
摘要

相似文献

1
SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report.肥大细胞增多症患者的新型冠状病毒2型感染：一项EPICOVIDEHA报告
J Investig Allergol Clin Immunol. 2023 Jun 15;33(3):225-227. doi: 10.18176/jiaci.0845. Epub 2022 Jul 27.
2
COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms.包括肥大细胞增多症在内的肥大细胞疾病患者感染新型冠状病毒肺炎不会影响肥大细胞活化症状。
J Allergy Clin Immunol Pract. 2021 May;9(5):2083-2086. doi: 10.1016/j.jaip.2021.02.023. Epub 2021 Feb 23.
3
Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome.肥大细胞增多症和单克隆肥大细胞活化综合征患者接种新型冠状病毒疫苗的安全性
J Allergy Clin Immunol Pract. 2021 Aug;9(8):3198-3199. doi: 10.1016/j.jaip.2021.05.010. Epub 2021 May 24.
4
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report.血液系统恶性肿瘤患者感染奥密克戎SARS-CoV-2变异株的结局：一项EPICOVIDEHA调查报告
Am J Hematol. 2022 Aug;97(8):E312-E317. doi: 10.1002/ajh.26626. Epub 2022 Jun 28.
5
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.接受替沙格韦单抗/西加韦单抗被动预先暴露免疫的血液系统恶性肿瘤合并 COVID-19 患者：EPICOVIDEHA 登记研究的配对分析。
J Hematol Oncol. 2023 Apr 1;16(1):32. doi: 10.1186/s13045-023-01423-7.
6
Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders.克隆性肥大细胞疾病患者的有效抗 SARS-CoV-2 免疫反应。
J Allergy Clin Immunol Pract. 2022 May;10(5):1356-1364.e2. doi: 10.1016/j.jaip.2021.12.038. Epub 2022 Jan 21.
7
SARS-CoV-2 vaccines are well tolerated in patients with mastocytosis.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗在肥大细胞增多症患者中耐受性良好。
Ann Allergy Asthma Immunol. 2022 Jun;128(6):733-734. doi: 10.1016/j.anai.2022.02.026. Epub 2022 Mar 4.
8
Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population.肥大细胞增多症和慢性髓性白血病患者中症状性新冠病毒感染的发生率：与奥地利普通人群的比较。
Eur J Haematol. 2023 Jan;110(1):67-76. doi: 10.1111/ejh.13875. Epub 2022 Oct 17.
9
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM).肥大细胞增多症患者的COVID-19疫苗接种：欧洲肥大细胞增多症专家网络（ECNM）和美国肥大细胞疾病倡议组织（AIM）的建议
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2139-2144. doi: 10.1016/j.jaip.2021.03.041. Epub 2021 Apr 5.
10
Delving Into COVID-19 Vaccination-Induced Anaphylaxis: Are mRNA Vaccines Safe in Mast Cell Disorders?深入研究新冠疫苗接种引起的过敏反应：mRNA疫苗在肥大细胞疾病中是否安全？
J Investig Allergol Clin Immunol. 2021 Apr 20;31(2):193-195. doi: 10.18176/jiaci.0680. Epub 2021 Feb 12.

引用本文的文献

1
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report.2023 - 2024年寒温带秋冬季节血液系统恶性肿瘤患者中的呼吸道病毒：EPICOVIDEHA - EPIFLUEHA报告
Am J Hematol. 2025 Mar;100(3):358-374. doi: 10.1002/ajh.27565. Epub 2024 Dec 23.
2
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.解读历史故事：2019冠状病毒病对血液系统恶性肿瘤患者的影响——2020年至2022年EPICOVIDEHA研究见解
EClinicalMedicine. 2024 Mar 18;71:102553. doi: 10.1016/j.eclinm.2024.102553. eCollection 2024 May.
3
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.
COVID-19合并血液系统恶性肿瘤重症患者的重症监护需求及预后：EPICOVIDEHA调查结果
Infection. 2024 Jun;52(3):1125-1141. doi: 10.1007/s15010-023-02169-7. Epub 2024 Feb 22.